Replimune's Second Act: How a Rejected Melanoma Drug Became an Approved Product in Four Months
Published on 08/19/2026 at 03:51 | Redaktion boerse-global.de
The distance between a 64 percent single-day collapse and a regulatory green light can be measured in months — and for Replimune, the journey took just under four. The biotech's stock now trades roughly sevenfold above its April nadir, a swing that captures both the brutality and the redemption arc embedded in small-cap drug development.
From 40 Patients to Full Approval
The turning point arrived on August 6, when the FDA granted accelerated approval to TUDRIQEV — the oncolytic viral therapy previously known as RP1 — in combination with Bristol Myers Squibb's Nivolumab for advanced melanoma. The decision reversed the agency's April 10 rejection of the same combination, a refusal that had triggered a cascade of selling and litigation.
The FDA's original concerns centered on an unplanned interim analysis built on data from just 40 patients — a tenth of the 400 initially planned for the study. That thin dataset became the foundation for multiple shareholder lawsuits accusing the company of obscuring the agency's reservations between October 20, 2025, and April 10, 2026.
The market's initial response to the rejection was unforgiving. Shares fell 19.46 percent to $4.76 on the day of the decision, then plunged another 64.29 percent to $1.70 three sessions later. Within days, a substantial portion of the company's market capitalization had evaporated.
Analysts Pile In as Commercial Launch Approaches
The approval has since rewritten the investment narrative. Replimune is now preparing the commercial rollout of TUDRIQEV, positioning it as a fresh option in the melanoma treatment landscape. Sunandana Chandra of Northwestern University has noted in media coverage that while oncolytic viral therapies face meaningful entry barriers, the product represents an important new therapeutic avenue.
Should investors sell immediately? Or is it worth buying Replimune?
Sell-side firms have responded in kind. Leerink upgraded the stock to "Outperform" on August 4, lifting its price target from $11 to $17. Wolfe Research has carried an "Outperform" rating since early August, while Wedbush initiated coverage with a Buy recommendation and a $12 target on August 7. Piper Sandler had already assigned a "Strong Buy" rating in late July.
The shares closed Tuesday at €13.46, up 6.4 percent on the session, extending a 30-day advance of roughly 54 percent. The secondary source pegs the month-over-month gain at 50 percent with the stock at €13.11, reflecting intraday movement. Either way, the momentum is unmistakable — as is the volatility that accompanies it. Annualized volatility stands at 347 percent, and the relative strength index of 66.8 suggests the rally has left visible marks on the chart without necessarily signaling an overbought condition.
The Numbers Behind the Comeback
Replimune's market capitalization now sits at approximately €1.21 billion, a figure that underscores how swiftly fortunes can reverse in this corner of the healthcare sector. The first-quarter earnings report, released Friday, showed a loss per share of $0.72 — slightly wider than the $0.69 consensus estimate.
Institutional investors have shown no signs of retreat. They collectively hold roughly 92.5 percent of the company's shares, and Quantinno Capital Management expanded its position by more than 780 percent during the first quarter, bringing its stake to 108,477 shares.
Insider activity tells a different story. Over the past 90 days, company executives sold 81,868 shares worth more than $1 million. On August 10, Chief Accounting Officer Andrew Schwendenman and Konstantinos Xynos both disposed of holdings at an average price of $12.97.
Legal Clouds Persist
The litigation stemming from the pre-approval period continues to wind through the courts. The Gross Law Firm has reminded investors that the lead plaintiff deadline falls on October 5, 2026, for shareholders who purchased stock during the window in question. Pomerantz LLP and SBS Law have also initiated actions against the company, its CEO Sushil Patel, and CFO Emily Hill.
For now, the approval appears to be outweighing the legal overhang in the market's assessment. The pattern is familiar across the biotech sector — Capricor Therapeutics and Pliant Therapeutics have shown similar dynamics in recent weeks, with sharp moves following regulatory headlines and subsequent legal or catalyst-driven follow-through.
Replimune's story is one of simultaneity: a company looking backward at a communications failure while looking forward to a product now on the market. For investors in binary-event stocks, that duality is the price of admission.
Ad
Replimune Stock: New Analysis - 19 August
Fresh Replimune information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
